Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies
26 February 2021 - 12:00AM
Business Wire
Implantable microdevice provides unique insight
into individual and combination therapy efficacy during early-stage
discovery
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced a strategic partnership with Kibur Medical to offer
exclusive access to its implantable microdevice (IMD) for in vivo
preclinical oncology studies.
Kibur’s Unique Technology
The IMD provides an opportunity to transform how researchers may
assess efficacy of oncology compounds in vivo as both individual
and combination therapies. Kibur’s microdevice technology can hold
up to 20 different compounds for local administration, which allow
it to:
- Measure interactions between disease tissue and microdoses of
therapies to predict the optimal drug regimen;
- Rapidly test multiple combinations at once in vivo in most
solid tumors;
- Dose therapies directly into disease tissue, allowing for
investigative studies of early-stage compounds where
pharmacokinetic properties are poorly understood.
Data-Driven Decisions
According to a study in Biostatistics, oncology drugs have a 97%
failure rate in clinical trials. Together with Charles River’s
leading expertise in early-stage preclinical testing, researchers
can utilize the Kibur technology to perform in vivo testing of
multiple doses and multiple combinations of oncology or
immune-oncology therapies in small cohorts of patient-derived
xenograft (PDX), cell-line derived or syngeneic models.
Additionally, Kibur’s IMD provides both a platform to observe
synergies of drug combinations and a time and cost-sensitive
testing solution for extending indications of existing oncology
drugs.
Excised tumor tissue is analyzed via multiplex
immuno-histochemistry, immune cell readouts, spatial
transcriptomics and MALDI-TOF mass spectrometry providing for rich
datasets in short cycle times and thereby improved decision making
early in the preclinical process.
Approved Quotes
- “We are proud to partner with Kibur Medical to help advance our
oncology service offering. The development of cancer therapies is
extremely nuanced, and Kibur’s technology provides clients with
important data on drug efficacy to help inform their preclinical
programs.” –Birgit Girshick, Corporate Executive Vice President,
Discovery and Safety Assessment, Biologics Testing Solutions, and
Avian Vaccine Services, Charles River
- “When looking for a strategic partner, we knew we wanted an
organization with global reach and a strong scientific bench.
Charles River’s longstanding reputation as an industry leader will
help deliver our technology to the widest possible network,
providing a huge opportunity to help develop the next generation of
cancer therapeutics.” – Oliver Jonas, PhD, Scientific Founder,
Kibur Medical
About Kibur Medical
Kibur Medical is a clinical stage biomedical company that
develops devices and microsensors for in vivo applications. The
company focuses on applications of its technology to develop
precision treatments for cancer and other diseases, as well as
enabling more efficient drug development in the preclinical and
clinical space.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210225005083/en/
Investors: Todd Spencer Corporate Vice President,
Investor Relations 781-222-6455 todd.spencer@crl.com
Media: Amy Cianciaruso Corporate Vice President, Public
Relations 781-222-6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2024 to May 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From May 2023 to May 2024